Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model
- 1 July 2018
- journal article
- research article
- Published by Elsevier in Antiviral Research
- Vol. 155, 89-96
Abstract
No abstract availableKeywords
Funding Information
- Health and Medical Research Fund (14131052)
- CEIRS (HHSN27220140006C)
- Theme Based Research Scheme (T11-705/14-N)
This publication has 24 references indexed in Scilit:
- Middle East Respiratory SyndromeNew England Journal of Medicine, 2017
- Central Role of ULK1 in Type I Interferon SignalingCell Reports, 2015
- The Same Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) yet Different Outbreak Patterns and Public Health Impacts on the Far East Expert Opinion from the Rapid Response Team of the Republic of KoreaInfection & Chemotherapy, 2015
- Tropism and replication of Middle East respiratory syndrome coronavirus from dromedary camels in the human respiratory tract: an in-vitro and ex-vivo studyThe Lancet Respiratory Medicine, 2014
- Cyclosporin A Inhibits Rotavirus Replication and Restores Interferon-Beta Signaling Pathway In Vitro and In VivoPLOS ONE, 2013
- Person-to-Person Spread of the MERS Coronavirus — An Evolving PictureNew England Journal of Medicine, 2013
- Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study GroupJournal of Virology, 2013
- Cyclosporin A inhibits hepatitis C virus replication and restores interferon‐alpha expression in hepatocytesTransplant Infectious Disease, 2010
- Mycophenolic Acid Inhibits Hepatitis C Virus Replication and Acts in Synergy With Cyclosporin A and Interferon-αGastroenterology, 2006
- Combined interferon α2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trialJournal of Gastroenterology, 2003